Shenzhen Neptunus Bioengineering ST海王
13 significant filings since 1 Jun 2026: 1 on share pledge, 1 on litigation and 1 on regulatory action, and 3 other kinds. The latest, on 28 Sep 2026: 关于转让控股子公司股权被动形成对外财务资助的公告. On 15 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to fall by 510.33% to 668.15% from the same period a year earlier.
自 1 Jun 2026 起有 13 份重大公告：share pledge 1 份、litigation 1 份、regulatory action 1 份，另有 3 类。最新一份（28 Sep 2026）：关于转让控股子公司股权被动形成对外财务资助的公告。15 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期下降 510.33% 至 668.15%。
Price History 价格走势
6,627 trading days 个交易日 · High 最高 ¥13.71 · Low 最低 ¥0.45| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥39亿 | ¥58亿 | 8th lowest of 30 · 30 家中第 8 低 | |
| Trailing P/E 市盈率 | — | 23.1x | No value 无数据 | |
| P/B 市净率 | 3.9x | 1.2x | 3rd highest of 30 · 30 家中第 3 高 | |
| Revenue Growth 营收增速 | -21.0% | 0.3% | 3rd lowest of 30 · 30 家中第 3 低 | |
| Profit Growth 净利增速 | -743.8% | -7.2% | Lowest of 30 · 30 家中第 1 低 | |
| Gross Margin 毛利率 | 9.3% | 11.2% | 11th lowest of 30 · 30 家中第 11 低 | |
| Net Margin 净利率 | -1.8% | 1.6% | 2nd lowest of 30 · 30 家中第 2 低 | |
| Return on Equity 净资产收益率 | -18.1% | 3.0% | Lowest of 30 · 30 家中第 1 低 | |
| Debt to Assets 资产负债率 | 92.2% | 61.0% | Highest of 30 · 30 家中第 1 高 | |
| Grade Score 评级得分 | 15 | 47 | Lowest of 30 · 30 家中第 1 低 |
Statement figures are for the period to 30 Jun 2026, filed by 30 of 30 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，30 家同业中 30 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Shanghai Pharma 上海医药 | ¥589亿 | 12.3x | 0.8x | 4.2% | 2.9% | 4.5% | C |
| Yifeng Pharmacy 益丰药房 | ¥272亿 | 15.5x | 2.3x | 3.5% | 8.8% | 8.0% | B |
| Jointown 九州通 | ¥249亿 | 12.4x | 0.9x | 7.6% | 1.4% | 4.2% | D |
| DaShenLin Pharmaceutical Group 大参林 | ¥202亿 | 14.8x | 2.7x | 3.5% | 7.2% | 11.6% | B |
| China National Medicines 国药股份 | ¥195亿 | 10.1x | 1.0x | 4.3% | 3.3% | 4.7% | C |
| China Meheco 中国医药 | ¥132亿 | 30.9x | 1.1x | -0.7% | 1.8% | 2.1% | D |
| Qingdao Baheal Medical 百洋医药 | ¥131亿 | 24.5x | 5.7x | -5.1% | 7.9% | 9.3% | C |
| China National Accord Medicines 国药一致 | ¥119亿 | 11.1x | 0.6x | -1.4% | 1.8% | 3.2% | D |
| Lbx Pharmacy Chain 老百姓 | ¥99亿 | 22.9x | 1.4x | 2.1% | 4.8% | 6.6% | C |
| C.Q. Pharmaceutical Holding 重药控股 | ¥89亿 | 24.9x | 0.8x | -2.6% | 0.8% | 2.2% | E |
| Shanghai C&D Innostic Medical Technology 建发致新 | ¥77亿 | 27.6x | 3.5x | 1.8% | 1.9% | 6.8% | D |
| Nanjing Pharmaceutical Group 南京医药 | ¥64亿 | 10.3x | 0.9x | -0.5% | 1.4% | 4.0% | D |
| Yixintang Pharmaceutical Group 一心堂 | ¥63亿 | 23.1x | 0.8x | -5.0% | 3.1% | 3.5% | C |
| Guangxi Liuyao Group 柳药集团 | ¥60亿 | 9.2x | 0.8x | 2.2% | 3.5% | 4.6% | C |
| Shenzhen Neptunus Bioengineering ST海王 | ¥39亿 | — | 3.9x | -21.0% | -1.8% | -18.1% | E |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。